EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieKohortenstudieOpen Access

Immune thrombocytopenia and pregnancy: an exposed/nonexposed cohort study

Stéphanie Guillet, Valentine Loustau, Emmanuelle Boutin, Anissa Zarour, Thibault Comont, Odile Souchaud-Debouverie, Nathalie Costedoat Chalumeau, Brigitte Pan-Petesch iD, Delphine Gobert, Stéphane Cheze, Jean Francois Viallard iD, Anne-Sophie Morin und 28 weitere

Blood · 05.01.2023 · 141 (1) · 11-21

DOI: 10.1182/blood.2022017277 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Blood, erschienen am 05.01.2023. Verfasst von Stéphanie Guillet und 39 weiteren Autor:innen. Beteiligte Einrichtung: Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l'adulte, Hôpital Henri Mondor, Assistance Publique Hôpitaux…. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Pregnancy Complications, Hematologic, Thrombocytopenia, Neonatal Alloimmune. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The risk of immune thrombocytopenia (ITP) worsening during pregnancy and neonatal ITP (NITP) have never been prospectively studied. We included 180 pregnant and 168 nonpregnant women with ITP in a prospective, multicenter, observational cohort study. A total of 131 pregnant women with ITP were matched to 131 nonpregnant women with ITP by history of splenectomy, ITP status (no response, response, complete response), and duration. Groups were followed for 15 months. The primary outcome was the first occurrence of ITP worsening defined by a composite end point including bleeding events and/or severe thrombocytopenia (<30 × 109/L) and/or ITP treatment modification. We also studied the recurrence of ITP worsening and the incidence of NITP and risk factors. The first occurrence of ITP worsening did not differ between pregnant and nonpregnant women with ITP (53.4 per 100 person-years [95% confidence interval {CI}, 40.8-69.9] vs 37.1 [95% CI, 27.5-50.0]; hazard ratio {HR}, 1.35 [95% CI, 0.89-2.03], P = .16). Pregnant women with ITP were more likely to have recurrence of severe thrombocytopenia and treatment modification (HR, 2.71 [95% CI, 1.41-5.23], P = .003; HR, 2.01 [95% CI, 1.14-3.57], P = .017, respectively). However, recurrence of severe bleeding events was not different between groups (P = .4). Nineteen (14%) neonates showed NITP <50 × 109/L. By multivariable analysis, NITP was associated with a previous offspring with NITP and maternal platelet count <50 × 109/L within 3 months before delivery (adjusted odds ratio, 5.55 [95% CI, 1.72-17.89], P = .004 and 4.07 [95% CI, 1.41-11.73], P = .009). To conclude, women with ITP do not increase their risk of severe bleeding during pregnancy. NITP is associated with NITP history and the severity of maternal ITP during pregnancy. These results will be useful for counseling women with ITP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombocytopenic, IdiopathicPregnancy Complications, HematologicThrombocytopenia, Neonatal AlloimmuneInfant, NewbornFemaleHumansPregnancyCohort StudiesProspective StudiesRetrospective StudiesNitroimidazolesTheophylline

Substanzen

7-(4'-(2-nitroimidazole-1-yl)butyl)theophyllineNitroimidazolesTheophylline

Autor:innen und Institutionen

  • Service de Médecine Interne, Centre national de référence des cytopénies auto-immunes de l'adulte, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris (AP-HP), Université Paris Est Créteil, Créteil, France.
  • Service de Médecine Interne, Centre Hospitalier Alpes Léman, Contamine sur Arve, France.
  • Unité de Recherche Clinique (URC Mondor), AP-HP, Hôpitaux Universitaires Henri Mondor, Créteil, France.
  • Univ Paris Est Créteil, INSERM, IMRB, Equipe CEpiA (Clinical Epidemiology and Ageing), Créteil, France.
  • Service de Médecine Interne et d'Immunopathologie-IUCT-Oncopole, CHU de Toulouse, Toulouse, France.
  • Service de Médecine Interne, CHU de Poitiers, Poitiers, France.

ORCID-Profile: Brigitte Pan-Petesch, Jean Francois Viallard, Manuel Cliquennois, Claire Fieschi, Karim Sacre, Jean Christophe Lega, Alexandra Benachi, Corentin Orvain, Sebastien Humbert, Florence Canoui-Poitrine

Zitieren

APA

Guillet, S., Loustau, V., Boutin, E., Zarour, A., Comont, T., Souchaud-Debouverie, O., Costedoat Chalumeau, N., Pan-Petesch, B., Gobert, D., Cheze, S., Viallard, J. F., Morin, A. S., Sauvetre, G., Cliquennois, M., Royer, B., Masseau, A., Terriou, L., Fieschi, C., Lambotte, O., …, & Godeau, B. (2023). Immune thrombocytopenia and pregnancy: an exposed/nonexposed cohort study. Blood, 141(1), 11-21. https://doi.org/10.1182/blood.2022017277

Vancouver

Guillet S, Loustau V, Boutin E, Zarour A, Comont T, Souchaud-Debouverie O, et al. Immune thrombocytopenia and pregnancy: an exposed/nonexposed cohort study. Blood. 2023;141(1):11-21. doi:10.1182/blood.2022017277

BibTeX
@article{Guillet2023,
  author = {Guillet, Stéphanie and Loustau, Valentine and Boutin, Emmanuelle and Zarour, Anissa and Comont, Thibault and Souchaud-Debouverie, Odile and Costedoat Chalumeau, Nathalie and Pan-Petesch, Brigitte and Gobert, Delphine and Cheze, Stéphane and Viallard, Jean Francois and Morin, Anne-Sophie and Sauvetre, Gaetan and Cliquennois, Manuel and Royer, Bruno and Masseau, Agathe and Terriou, Louis and Fieschi, Claire and Lambotte, Olivier and Girault, Stéphane and Lioger, Bertrand and Audia, Sylvain and Sacre, Karim and Lega, Jean Christophe and Langlois, Vincent and Benachi, Alexandra and Orvain, Corentin and Devidas, Alain and Humbert, Sebastien and Gambier, Nicolas and Ruivard, Marc and Zarrouk, Virginie and Ebbo, Mikael and Willems, Lise and Segaux, Lauriane and Mahevas, Matthieu and Haddad, Bassam and Michel, Marc and Canoui-Poitrine, Florence and Godeau, Bertrand},
  title = {Immune thrombocytopenia and pregnancy: an exposed/nonexposed cohort study},
  journal = {Blood},
  year = {2023},
  volume = {141},
  number = {1},
  pages = {11--21},
  doi = {10.1182/blood.2022017277}
}
Kostenlos starten →